- Home
- VCRE vs NVG Comparison
VCRE vs NVG Comparison
Compare VCRE & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | VCRE | NVG |
|---|---|---|
| Founded | N/A | 1999 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VCRE | NVG |
|---|---|---|
| Price | $11.53 | $12.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.1K | ★ 466.4K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.50 | $11.53 |
| 52 Week High | $12.85 | $13.59 |
Technical Indicators
Market Signals| Indicator | VCRE | NVG |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 39.76 |
| Support Level | $11.00 | N/A |
| Resistance Level | $12.85 | $12.80 |
| Average True Range (ATR) | 0.31 | 0.12 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 85.48 | 15.39 |
Price Performance
Historical ComparisonAbout VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
About NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.